---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-072814"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:18:55.821200+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M

## Summary
- Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.
- Acquisition funded by existing cash and $150M convertible notes at 4.00% due 2030; expects closing in September 2025.
- Q2 2025 net revenue $39.7M (vs $0.8M YoY); net income $19.8M ($0.29 EPS) vs net loss $14.2M in Q2 2024.
- Adjusted EBITDA Q2 2025 $22.4M; operating expenses $18.3M up 18% YoY driven by G&A and R&D.
- Contingent payments up to $25M if FDA approves REZZAYO for prophylaxis in stem cell transplant by June 2029.

## SEC filing metadata
- accession: 0001213900-25-072814
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/0001213900-25-072814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea0252043-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-072814
- JSON: https://secwatch.observer/filing/0001213900-25-072814.json
- Plain text: https://secwatch.observer/filing/0001213900-25-072814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.